The lacrimal devices market is valued at USD 32.1 million in 2025, and is expected to grow to USD 57.0 million by 2035, reflecting a 5.9% CAGR. North America will retain the largest regional share, buoyed by the United States’ well-funded tertiary eye-care ecosystem, while Germany anchors Western Europe and China propels East Asian uptake. Product leadership rests with bicanalicular lacrimal duct stent tubes, which capture about three-quarters of 2025 sales and are expanding the fastest as surgeons favour their material compatibility and ease of placement.
Lacrimal Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Estimated Size, 2025 | USD 32.1 million |
| Projected Size, 2035 | USD 57.0 million |
| Value-based CAGR (2025 to 2035) | 5.9% |
Momentum is underpinned by two converging clinical realities: a rising incidence of nasolacrimal duct obstruction (NLDO) in paediatric and geriatric populations, and a clear shift toward minimally invasive dacryocystorhinostomy (DCR) techniques that routinely require temporary stenting. Hospitals absorb nearly half of global spending because they integrate paediatric ophthalmology, day-care surgery, and post-operative imaging under one roof, streamlining reimbursement and follow-up.
Simultaneously, longer life expectancy, screen-intensive lifestyles, and chronic ocular drug use are enlarging the pool of adults who develop secondary NLDO or dry-eye complications-conditions that increasingly prompt early referral for endoscopic DCR supported by silicone or polyurethane stents.
Looking ahead, growth will hinge on biomaterial innovation, device miniaturisation, and regional manufacturing. Developers are prototyping bio-absorbable stents that eliminate removal visits, smart tubes with micro-sensors for real-time patency monitoring, and pre-loaded delivery systems that cut operative time.
Partnerships between multinational device firms and local distributors are multiplying in India, South Korea, and Brazil, where fertility rates remain high and ophthalmic infrastructure is expanding. At the policy level, harmonised NLDO treatment guidelines and faster regulatory pathways are encouraging insurers to reimburse advanced lacrimal implants, reinforcing a virtuous growth cycle through 2035.
The below table presents the expected CAGR for the global sales of lacrimal devices over several semi-annual periods spanning from 2025 to 2035. In the first half (H1) of the decade from 2024 to 2035, the business is predicted to surge at a CAGR of 7.0%, followed by a slightly lower growth rate of 6.6% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.0% (2024 to 2034) |
| H2 | 6.6% (2024 to 2034) |
| H1 | 5.9% (2025 to 2035) |
| H2 | 5.5% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 5.9% in the first half and decrease moderately at 5.5% in the second half. In the first half (H1) the market witnessed a decrease of 110.0 BPS while in the second half (H2), the market witnessed a increase of 110.0 BPS.
The lacrimal devices market is segmented by product, end user, and region. By product, the market includes monocanalicular lacrimal duct stent tubes and bicanalicular lacrimal duct stent tubes. In terms of end user, the market is divided into hospitals, ophthalmic clinics, and ambulatory surgical centers. Regionally, the market is segmented into North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and the Middle East and Africa.
The bicanalicular lacrimal duct stent tube segment is expected to register the fastest growth, is projected to grow at a CAGR of 7.2%, commanding approximately 52% of the total market share by 2035, up from around 44% in 2025. Bicanalicular stents are commonly preferred in bilateral nasolacrimal duct obstructions and post-DCR surgeries due to their dual-canaliculus anchoring and reduced extrusion risk. These attributes contribute to their broad clinical adoption in both adult and complex pediatric cases.
This expansion is fueled by higher deployment rates in tertiary care hospitals and rising procedure volumes in East Asia and Europe. The segment also benefits from higher reimbursement alignment in developed healthcare systems, which further supports procedural uptake. Additionally, growing awareness among ophthalmologists about improved long-term patency rates is accelerating early product preference.
In contrast, monocanalicular stent tubes, though effective for simpler and unilateral tear duct blockages, are expected to witness muted growth due to narrower clinical indications and declining usage in adult populations. Adoption is largely limited to pediatric ophthalmology and minor procedures, restricting revenue expansion.
| End User Segment | CAGR (2025 to 2035) |
|---|---|
| Bicanalicular Lacrimal Duct Stent Tube | 7.2% |
The hospitals segment is projected to lead growth in the lacrimal devices market over the forecast period, emerging as the most lucrative end-user category. Hospitals are forecasted to grow at a CAGR of 6.8%, capturing nearly 58% of the total market share by 2035. This growth is driven by high surgical throughput, access to advanced ophthalmic infrastructure, and the availability of trained oculoplastic specialists. Hospitals also handle the majority of dacryocystorhinostomy (DCR) procedures and complex bilateral cases, which aligns with increased adoption of bicanalicular stents the fastest-growing product segment.
In contrast, ophthalmic clinics are expanding steadily, particularly in urban outpatient settings, offering routine tear duct care and diagnostics. Ambulatory surgical centers (ASCs), while gaining importance for cost-effective and same-day interventions, continue to represent a smaller market share due to limited infrastructure for advanced oculoplastic procedures.
| End User Segment | CAGR (2025 to 2035) |
|---|---|
| Hospitals | 6.8% |
Advancement in Nasolacrimal Duct Obstruction Treatment Demands the use of Lacrimal Devices
With over one fifth of newborns with nasolacrimal duct obstruction disorder, the treatment approach is often decided based on how severe it is. Earlier, ophthalmologists used to consider conservative approach with anti-inflammatory and antibiotics for the treatment, which showed limited effectivity. With dacryocystorhinostomy (DCR) procedure, management of the lacrimal duct obstruction became easier with high success rate.
Usage of lacrimal duct stent tube for the correction of lacrimal duct or in building completely new lacrimal duct, resulted in superior efficacy with greater success rate as compared to conservative approach.
Lacrimal stent provides more safer and effective approach for the management of lacrimal duct obstruction. Various manufacturers are introducing new lacrimal duct stent tubes made of different material and length and this results in more personalized approach in treating nasolacrimal duct obstruction.
In this decade, manufacturers in the lacrimal duct stent tube market focused on correcting their product to enhance patient compliance, resulting in enhanced ophthalmologist's preference for lacrimal duct stent tubes over other devices such as catheters.
Increasing Number of Births and Decreasing Infant Mortality Rate increased Demand in Market
Very high number of births coupled with falling infant mortality has greatly enhanced market demand for this product sector, particularly in countries like India and China, where the fertile population is on the rise. These nations significantly contribute to the world newborn population each year.
Developing regions in Asia and Africa have the most number of population additions, due to improved access to healthcare, increased investment in neonatal care, and governmental initiatives. This demographic expansion bolsters demand for infant products and services, thereby giving these regions considerable significance in market expansion.
Advancements in medicine and industrial revolution are immediate factors assisting to the increasing number of newborn population each year. Developed countries are also initiating various programs to keep up with the existing fertile population ratio to that of overall population.
Advancements in the field of medicine, initiatives by World Health Organization, UNICEF, etc. to tackle the infant mortality have also assisted increased newborn survival with reduced infant mortality. In 1990, there were around 5 million newborns whereas in 2023, it is halved due to various initiatives by global. With increasing number of newborns in year-on-year basis, it is expected to assist the growth of the lacrimal duct stent tube market.
Greater Focus on Product Awareness will Create Opportunities in the Market
Increasing awareness about the availability and subsequent adoption of lacrimal duct stent tube devices are expected to generate significant revenue. Awareness about the availability and efficacy among healthcare professionals is expected to play a major role in increased adoption of devices for nasolacrimal duct obstruction management.
There are various variants of lacrimal duct stent tube available in the market, which represents vast revenue generation opportunity.
The Lacrimal Devices sector is on the verge of growth, a growth engendered by rising awareness about the devices that feel their way into the lacrimal duct stent tube group. With the ability to treat na-solacrimal duct obstructions, these devices are becoming very popular as they can aid in the restoration of proper tear passage and have been known to facilitate improvements in patient outcomes.
The increasing knowledge among healthcare providers of the existence and efficacy of these devices has helped them gain foothold in the market.
The availability of lacrimal duct stent tubes is numerous and offers varied commercial opportunities. Innovative technology includes device design, materials, and less invasive surgical options adopted for these products that entice the ophthalmologists and the surgeons.
The demand within the Lacrimal Devices segment is further boosted by the increasing prevalence of lacrimal system disorders, especially in aging populations, and the increase in awareness about ophthalmic health. Emerging economies in Asia-Pacific, Africa, and the Middle East are anticipated to provide very lucrative opportunities as healthcare infrastructure expands and access to advanced therapeutic deliveries continues to grow.
Complications Associated with Lacrimal Duct Stent Tube May Restrict the Market
In dacryocystorhinostomy (DCR) procedure, several complications such as corneal abrasion, canaliculitis, prolapse, etc. may occur. Lacrimal duct stent tubes may be displaced and come out via lacrimal duct towards eye or nasal cavity, resulting in uneasiness and rarely resulting in false passage creation during intubation, cheese wiring of the punctum.
Although, manufacturers in the lacrimal duct stent tube market are correcting the flaws by altering the length, the material used for manufacturing, etc., the process still has risk of complications, considering the age group in which stenting is carried out. These complications may hamper the potential growth of the market.
Despite the fact that manufacturers in the lacrimal devices space are fixing problems by changing the length, manufacturing material, and other factors, the method still poses a risk of difficulties, especially given the age range for which stenting is performed. These problems may limit the market's future expansion.
The majority of lacrimal devices manufacturers are based in developed regions such as North America and Europe. Latin America, East and South Asia, and other developing nations frequently rely on western manufacturers. As a result, product availability is constrained in a number of high-revenue-potential locations, stifling market expansion.
Manufacturers who do not have a regional production plant rely on multiple regional or country-level distributors to get their goods into the market. It frequently leads to increased product costs and limited availability. Despite the fact that manufacturers are eager to expand their regional product footprints, their efforts are still limited.
The evaluation of lacrimal devices safety is an important part of the development process, which can be challenging. The market for lacrimal devices is hampered by the problems described above.
Companies in Tier 1 are those dominant in the market with significant shares, driven by their investment in R&D, strategic partnerships, and standpoints in clinical trials for the innovativeness of lacrimal device solutions.
Companies like FCI Ophthalmics, Kaneka Corporation, Gunther Weiss Scientific Glass, and Bess Medizintechnik dominate the lacrimal device market by offering advanced, high-quality medical devices for treatment of a variety of ailments of the lacrimal system. They are noted for being truly global companies committed to innovations that maintain their leadership.
Tier 2 companies are dominant in a regional market mainly through inexpensive manufacturing processes in collaboration with their research institutions. These companies cannot compete with Tier 1 on a global level, but are rather suppliers that provide unique contributions toward very specific regional markets, with affordable specialized lacrimal devices aimed at meeting local needs.
Tier 3 companies cater to specialty or niche markets through providing niche lacrimal devices for certain applications. Although their share is small, they add a limited contribution to the market, addressing some special needs in lacrimal care and injecting diversity and innovation into the overall landscape of the market.
The section below covers the industry analysis for the lacrimal devices across different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and MEA, is provided.
The United States is anticipated to remain at the forefront in North America, with higher market share through 2035. In Asia Pacific, India is projected to witness a CAGR of 6.4% by 2035.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 5.4% |
| Germany | 5.9% |
| China | 5.6% |
| France | 5.8% |
| India | 6.4% |
| Spain | 5.3% |
| South Korea | 6.2% |
The sales in United States lacrimal devices is expected to grow at a CAGR of 5.4% between 2025 and 2035. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
The North America market will reportedly be accounting for a near one-third share during the research phase because of its well-established medical industry and high healthcare spending. The upsurge in demand for lacrimal devices has been influenced by growing advances in ophthalmology facilities, with concomitant surges in the incidence of lacrimal diseases.
The positive trend is being complemented by increased per capita health care spending and supportive government initiatives that promote integrated health care systems, leading to enhanced access for consumers to advanced treatments and driving adoption rates.
Coupled with an increasing prevalence of retinal disorders, these present lucrative opportunities for market participants since these pathologies are largely treated with adjunctive ophthalmic interventions. Overall, this is expected to enable the USAto lead toward global lacrimal device marketplace development.
China’s lacrimal devices market is poised to exhibit a CAGR of 7.6% between 2025 and 2035. Currently, it holds the highest share in the East Asia market, and the trend is expected to continue during the forecast period.
China's lacrimal devices market is expected to witness growth on account of several factors. Firstly, the booming healthcare infrastructure in the country is improving the access to advanced therapies, including lacrimal devices. Secondly, the rising awareness among patients regarding ophthalmic health and improved diagnostics capabilities are increasingly convincing patients to seek treatment for disorders affecting the lacrimal passages.
Additionally, the rising prevalence of disorders associated with age, dry eye syndrome, like congenital lacrimal duct obstructions, coupled with the expansion towards minimally invasive treatment options, is directly influencing the growing demand for lacrimal devices. These factors, among several others, will be working to provide significant growth in the market.
The sales of lacrimal devices in Germany is poised to exhibit a CAGR of 8.0% between 2025 and 2035. Currently, it holds the highest share in the Western Europe market, and the trend is expected to continue during the forecast period.
Germany's strength is founded on the regulatory framework for surgical devices that is well-defined and the growing effort of the population to understand treatments for lacrimal duct obstruction and related health problems. This set of conditions has favoured the penetration of advanced lacrimal devices in the country.
For meeting the demands of the patients in an effective way, companies in the industry have nurtured a very healthy relationship with the hospitals and the ophthalmic clinics along with direct channels for hospitals and clinics for access to these products. Additionally, companies are involved in strategic partnerships and acquiring major clinics and hospitals within Germany.
These initiatives are aimed at improving their operations, extending market reach, and catering to the ever-increasing demand for innovation in treatments for lacrimal systems in the region.
Leading lacrimal device manufacturers are focusing on geographic growth in order to increase revenue and expand their sales presence in emerging markets by acquiring local market players.
Recent Industry Developments in Lacrimal Devices Industry
| Report Attributes | Details |
|---|---|
| Current Total Market Size (2025) | USD 32.1 million |
| Projected Market Size (2035) | USD 57.0 million |
| CAGR | 5.9% |
| Base Year for Estimation | 2024 |
| Historical Period | 2020 to 2024 |
| Projections Period | 2025 to 2035 |
| Report Parameter | Revenue in USD million/Volume in Units |
| Product/Service Segments Analyzed | Monocanalicular Lacrimal Duct Stent TubE, Bicanalicular Lacrimal Duct Stent Tube |
| End Users Analyzed | Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Countries Covered | United States, Japan, Germany, India, United Kingdom, France, Italy, Brazil, Canada, South Korea, Australia, Spain, Netherlands, Saudi Arabia, Switzerland |
| Key Players | FCI Ophthalmics, Kaneka Corporation (Kaneka Pharma America LLC), Gunther Weiss Scientific Glass, Bess Medizintechnik GmBH. |
| Additional Attributes | Market share by company, technological advancements, regulatory compliance, regional adoption insights, company profiles |
| Customization and Pricing | Available upon request |
In terms of product, the industry is divided into- monocanalicular lacrimal duct stent tube and bicanalicular lacrimal duct stent tube
In terms of end user, the industry is segregated into hospitals, ophthalmic clinics and ambulatory surgical centers
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global lacrimal devices market is expected to reach USD 57.0 million by 2035, up from USD 32.1 million in 2025, registering a CAGR of 5.9% over the forecast period.
Bicanalicular lacrimal duct stent tubes are the leading product segment, projected to grow at a CAGR of 7.2% and account for approximately 52% of the market share by 2035.
India is projected to be the fastest-growing country in the lacrimal devices market, with a CAGR of 6.4% from 2025 to 2035, driven by rising procedure volumes and expanding healthcare infrastructure.
Hospitals are the dominant end-user segment, expected to account for 58% of the total market share by 2035, growing at a CAGR of 6.8%, supported by high-volume DCR procedures and access to specialized care.
Bicanalicular stents are preferred due to dual-canaliculus anchoring, reduced extrusion risk, and better surgical outcomes, especially in bilateral obstructions and post-DCR surgeries. Higher reimbursement and clinical efficacy further fuel their adoption.
Explore Therapeutic Device Insights
Lacrimal Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
